Skip to main navigation
Skip to main content
Passage Bio Logo Passage Bio Logo

Investor Relations

  • Home
    • Company
      • About Passage Bio
      • Management Team
      • Board of Directors
    • Science & Technology
      • Our GTP Partnership
      • Vector Selection and Delivery
      • Manufacturing
    • Pipeline
      • GM1 Gangliosidosis
      • Frontotemporal Dementia
      • Krabbe Disease
    • Patients & Families
      • Penn Orphan Disease Center
      • Rare Disease Facts
      • Natural History Study
    • Investors & Media
      • Overview
      • News & Events
        • Press Releases
        • Events & Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Investment Calculator
        • Analyst Coverage
      • Financials & Filings
        • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
      • Investor Resources
        • Investor FAQs
        • Investor Contact
        • Email Alerts
    • Careers
    • Contact

Press Releases

Investor Relations

  • Home
    • Company
      • About Passage Bio
      • Management Team
      • Board of Directors
    • Science & Technology
      • Our GTP Partnership
      • Vector Selection and Delivery
      • Manufacturing
    • Pipeline
      • GM1 Gangliosidosis
      • Frontotemporal Dementia
      • Krabbe Disease
    • Patients & Families
      • Penn Orphan Disease Center
      • Rare Disease Facts
      • Natural History Study
    • Investors & Media
      • Overview
      • News & Events
        • Press Releases
        • Events & Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historic Price Lookup
        • Investment Calculator
        • Analyst Coverage
      • Financials & Filings
        • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
      • Investor Resources
        • Investor FAQs
        • Investor Contact
        • Email Alerts
    • Careers
    • Contact

Press Releases

January 11, 2021
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
January 4, 2021
Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

Investor Tools

  • Email Alerts
  • RSS Feeds
  • FAQs
  • Investor Contact
Passage Bio Logo

Contact

General inquiries: info@passagebio.com

Investors Contact: passagebio@sternir.com

Two Commerce Square
2001 Market Street, 28th Floor
Philadelphia, PA
19103

Email Alerts

Required fields denoted by an asterisk ().
Alert type
© Passage BIO, Inc.. All Rights Reserved

Footer Links - Policy

Privacy Policy